Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases
- Written by Viw Magazine
- Secarna's LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases
- Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation
- With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells and strong symptom relief and significant prolongation of survival was achieved in a CAPS disease model.
